Taisho Makes Japan Vornorexant Filing, Hopes To Dent Insomnia Market

Potential Half-Life Advantage

 
• By Lisa Takagi

Taisho’s in-house insomnia therapeutic candidate vornorexant offers a potential advantage of a shorter half-life compared to its competitors, which can contribute to patients’ QOL.

Taisho filed for vornorexant's global first approval in Japan.
Taisho files vornorexant's for global first approval in Japan. • Source: Shutterstock

More from Japan

More from Focus On Asia